Randomized, double‐blind, placebo‐controlled, dose‐escalating phase I, healthy subjects study of intravenous OPN‐305, a humanized anti‐TLR2 antibody

M Reilly, RM Miller, MH Thomson… - Clinical …, 2013 - Wiley Online Library
Upregulation of Toll‐like receptor 2 (TLR2) plays a critical role in inflammation associated
with ischemia/reperfusion–induced tissue damage. OPN‐305 is the first humanized IgG4 …
被引用次数：141 相关文章

Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.

M Reilly, RM Miller, MH Thomson, V Patris… - Clinical …, 2013 - europepmc.org
Upregulation of Toll-like receptor 2 (TLR2) plays a critical role in inflammation associated
with ischemia/reperfusion–induced tissue damage. OPN-305 is the first humanized IgG4 …
[PDF] scienceopen.com

[PDF][PDF] Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

M Reilly, RM Miller, MH Thomson… - CLINICAL …, 2013 - scienceopen.com
Given the high degree of conservation of TLR2 sequence homology across species (eg,
human and cynomolgus monkey TLR2 share absolute identity of 96.18%), OPN-305 and …

[引用][C] Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

M REILLY, RM MILLER, B KEOGH… - Clinical …, 2013 - pascal-francis.inist.fr
Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects
Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody CNRS Inist Pascal-Francis …

[引用][C] Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

M Reilly, RM Miller, MH Thomson, V Patris… - Clinical Pharmacology …, 2013 - cir.nii.ac.jp
Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy
Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody | CiNii Research …

Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody

M Reilly, RM Miller, MH Thomson… - Clinical …, 2013 - pubmed.ncbi.nlm.nih.gov
Upregulation of Toll-like receptor 2 (TLR2) plays a critical role in inflammation associated
with ischemia/reperfusion-induced tissue damage. OPN-305 is the first humanized IgG4 …
[HTML] nih.gov

[HTML][HTML] Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

M Reilly, RM Miller, MH Thomson, V Patris… - Clinical …, 2013 - ncbi.nlm.nih.gov
Upregulation of Toll-like receptor 2 (TLR2) plays a critical role in inflammation associated
with ischemia/reperfusion–induced tissue damage. OPN-305 is the first humanized IgG4 …

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

M Reilly, RM Miller, MH Thomson, V Patris… - Clinical …, 2013 - research.rug.nl
Upregulation of Toll-like receptor 2 (TLR2) plays a critical role in inflammation associated
with ischemia/reperfusion-induced tissue damage. OPN-305 is the first humanized IgG4 …

Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.

M Reilly, RM Miller, MH Thomson, V Patris… - Clinical …, 2013 - europepmc.org
Upregulation of Toll-like receptor 2 (TLR2) plays a critical role in inflammation associated
with ischemia/reperfusion–induced tissue damage. OPN-305 is the first humanized IgG4 …

[引用][C] Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

M REILLY, RM MILLER… - Clinical …, 2013 - Nature Publishing Group